Results 1 to 10 of about 12,783,707 (261)

Iris Metastasis from Small-Cell Lung Cancer

Türk Oftalmoloji Dergisi, 2013
Uveal metastasis is the most common intraocular malignancy. In order of frequency, it affects choroid, iris, and ciliary body. We report herein the clinicopathologic features and response to therapy in a patient with iris metastasis from a small-cell ...
Samuray Tuncer, Dilbade Yıldız Ekinci, Emin Darendeliler, Pınar Fırat   +3 more
doaj   +2 more sources

Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)

Chinese Journal of Lung Cancer, 2023
With the development of precision diagnosis and treatment for non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, as a rare subset of EGFR mutaions, have gradually attracted attention ...
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
doaj   +1 more source

Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer

Chinese Journal of Lung Cancer, 2023
Corona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases ...
Non-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical Oncology, China Medical Education Association   +1 more
doaj   +1 more source

MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties

Frontiers in Oncology, 2020
MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers.
Sumei Wang, Sumei Wang, Sumei Wang, Nayan Liu, Nayan Liu, Nayan Liu, Nayan Liu, Qing Tang, Qing Tang, Qing Tang, Honghao Sheng, Honghao Sheng, Honghao Sheng, Shunqin Long, Shunqin Long, Shunqin Long, Wanyin Wu, Wanyin Wu, Wanyin Wu   +18 more
doaj   +1 more source

Chinese Expert Consensus on the Standardized Diagnosis and Treatment of 
Non‑small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

Chinese Journal of Lung Cancer
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj   +1 more source

Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population. [PDF]

PLoS ONE, 2017
Non-small cell lung cancer is one of the most common cancers and the leading cause of cancer death worldwide. Genetic variants in regulatory regions of some miRNAs might be involved in non-small cell lung cancer susceptibility and survival. rs12220909 (G/
Lixia Fan, Linqi Chen, Xiaoling Ni, Shicheng Guo, Yinghui Zhou, Chenji Wang, Yabiao Zheng, Fangyuan Shen, Vijay Kumar Kolluri, Merlin Muktiali, Zhenhong Zhao, Junjie Wu, Dunmei Zhao, Zhenglei He, Xulong Feng, Ziyu Yuan, Juan Zhang, Li Jin, Jiucun Wang, Minghua Wang   +19 more
doaj   +1 more source

Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy 
for SCLC

Chinese Journal of Lung Cancer
Small cell lung cancer (SCLC), characterized by high aggressiveness, early metastasis, and poor prognosis, has long been a major challenge in lung cancer treatment.
Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology
doaj   +1 more source

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

Chinese Journal of Lung Cancer, 2021
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T ...
Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer   +1 more
doaj   +1 more source

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Drugs in Context, 2023
BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes
Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti   +5 more
doaj   +1 more source

Synthetic circRNA therapeutics: innovations, strategies, and future horizons

MedComm
Small molecule drugs are increasingly emerging as innovative and effective treatments for various diseases, with mRNA therapeutics being a notable representative.
Jingsheng Cai, Zonghao Qiu, William Chi‐Shing Cho, Zheng Liu, Shaoyi Chen, Haoran Li, Kezhong Chen, Yun Li, Chijian Zuo, Mantang Qiu   +9 more
doaj   +1 more source